Emily Goodlett, APRN
Family · Frankfort, KYNPI 1730521436
Payments from drug & device makers
Across 318 payments — averaging $14.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$508
- GSK$352
- Novo Nordisk$334
- AstraZeneca$270
- Astellas Pharma US Inc$172
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,40296%
- Education$1644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $1,707 |
| Lilly USA, LLC | 40 | $508 |
| GSK | 19 | $352 |
| Novo Nordisk | 22 | $334 |
| AstraZeneca | 14 | $270 |
| Astellas Pharma US Inc | 6 | $172 |
| Amgen | 9 | $133 |
| Otsuka America Pharmaceutical, Inc. | 7 | $131 |
| Pfizer | 7 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $107 |
| Alkermes, Inc. | 4 | $102 |
| Boehringer Ingelheim | 6 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Lundbeck LLC | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Radius Health, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Dexcom, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Corcept Therapeutics | 1 | $20 |
| Merck | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,566 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $103,927 |
| VraylarCariprazine Hcl | 58 | $85,928 |
| FarxigaDapagliflozin Propanediol | 87 | $65,748 |
| JardianceEmpagliflozin | 63 | $55,100 |
| RybelsusSemaglutide | 28 | $50,029 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $32,292 |
| MounjaroTirzepatide | 29 | $30,990 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $29,660 |
| Spiriva RespimatTiotropium Bromide | 40 | $27,532 |
| XareltoRivaroxaban | 25 | $26,170 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $24,621 |
| ProliaDenosumab | 13 | $22,297 |
| LinzessLinaclotide | 29 | $20,868 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,786 |
| EliquisApixaban | 23 | $17,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $334 | $153,956111 claims |
| AbbVieVraylar, Linzess | $1,707 | $106,79587 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $94 | $95,153123 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $270 | $81,473115 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $352 | $73,719112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $508 | $44,49543 claims |
| Johnson & JohnsonXarelto | $44 | $26,17025 claims |
| AmgenProlia | $133 | $22,29713 claims |
| MerckJanuvia, Belsomra | $17 | $21,04828 claims |
| PfizerEliquis | $108 | $17,97423 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $16,39419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Frankfort
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.